Igm Biosciences Inc Quick Ratio (IGMS) starting from the second quarter 2025 to second quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Igm Biosciences Inc   (NASDAQ: IGMS)

Igm Biosciences Inc 's Quick Ratio

IGMS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Igm Biosciences Inc 's Cash & cash equivalent, this led to improvement in Igm Biosciences Inc 's Quick Ratio to 17.21, above Igm Biosciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 39 other companies have achieved higher Quick Ratio than Igm Biosciences Inc in second quarter 2025. While Quick Ratio total ranking has improved so far during the Q2 2025 to 145, from total ranking in the first quarter 2025 at 353.

Explain Quick Ratio?
How much Cash & cash equivalents IGMS´s has?
What are IGMS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IGMS Quick Ratio (Jun 30 2025)
Q2		 (Mar 31 2025)
Q1		 (Dec 31 2024)
Q4		 (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2
Y / Y Current Liabilities Change -83.91 % -25.66 % -11.4 % 2.33 % -15 %
Y / Y Cash & cash equivalent Change -59.32 % -48.22 % -45.57 % -43.46 % -33.73 %
Quick Ratio MRQ 17.21 5.39 4.88 4.98 6.81
IGMS's Total Ranking # 145 # 353 # 382 # 497 # 416
Seq. Current Liabilities Change -78.51 % -25.08 % -14.39 % 16.75 % -0.73 %
Seq. Cash & cash equivalent Change -31.43 % -17.23 % -16 % -14.66 % -12.73 %



Quick Ratio second quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 40
Healthcare Sector # 58
Overall Market # 145


Quick Ratio Statistics
High Average Low
37.68 13.48 4.88
(Sep 30 2019)   (Dec 31 2024)




Financial Statements
Igm Biosciences Inc 's Current Liabilities $ 6 Millions Visit IGMS's Balance sheet
Igm Biosciences Inc 's Cash & cash equivalent $ 104 Millions Visit IGMS's Balance sheet
Source of IGMS's Sales Visit IGMS's Sales by Geography


Cumulative Igm Biosciences Inc 's Quick Ratio

IGMS's Quick Ratio for the trailling 12 Months

IGMS Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -28.05 % -12.06 % -9.34 % -7.72 % -9.07 %
Y / Y Cash & cash equivalent TTM Growth -48.31 % -42.29 % -35.84 % -29.71 % -23.04 %
Quick Ratio TTM 5.69 5.5 6.06 6.83 7.92
Total Ranking TTM # 2931 # 2984 # 1788 # 3022 # 2943
Seq. Current Liabilities TTM Growth -21.43 % -6.19 % -2.99 % 0.62 % -3.96 %
Seq. Cash & cash equivalent TTM Growth -18.75 % -14.87 % -13.91 % -13.19 % -9.29 %

Quick ratio ranking by company, industry and sector >> Back to IGMS Financial Strength Comparisons >> Go to Compare IGMS Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Igm Biosciences Inc 's average Cash & cash equivalent, this led to increase in in Igm Biosciences Inc 's Quick Ratio to 5.69, Quick Ratio remained below IGMS average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 401 other companies have achieved higher Quick Ratio than Igm Biosciences Inc . While Quick Ratio overall ranking has improved so far to 2931, from total ranking during the twelve months ending first quarter 2025 at 2984.

Explain Quick Ratio?
How much Cash & cash equivalents IGMS´s has?
What are IGMS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 402
Healthcare Sector # 827
Within the Market # 2931


trailing twelve months Quick Ratio Statistics
High Average Low
25.62 11.24 2.52
(Jun 30 2020)   (Sep 30 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Janux Therapeutics Inc   46.59 $ 996.011  Millions$ 21.379  Millions
Essa Pharma inc   41.85 $ 85.975  Millions$ 2.054  Millions
Xbiotech Inc   39.65 $ 152.938  Millions$ 3.857  Millions
Roivant Sciences Ltd   39.55 $ 4,503.151  Millions$ 113.866  Millions
Apimeds Pharmaceuticals US, Inc.  36.67 $ 8.735  Millions$ 0.238  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Upstream Bio Inc   36.01 $ 393.581  Millions$ 10.929  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Protagonist Therapeutics inc   30.59 $ 570.465  Millions$ 18.646  Millions
Edgewise Therapeutics inc   28.43 $ 593.992  Millions$ 20.896  Millions
Arca Biopharma Inc  27.12 $ 328.406  Millions$ 12.110  Millions
Inhibitor Therapeutics Inc   26.70 $ 3.738  Millions$ 0.140  Millions
Hoth Therapeutics Inc   26.26 $ 9.014  Millions$ 0.343  Millions
Viking Therapeutics Inc   25.63 $ 807.724  Millions$ 31.512  Millions
Bicara Therapeutics Inc   25.34 $ 436.606  Millions$ 17.227  Millions
Monopar Therapeutics Inc   24.94 $ 39.502  Millions$ 1.584  Millions
Design Therapeutics Inc   24.73 $ 216.276  Millions$ 8.747  Millions
Terns Pharmaceuticals Inc   24.43 $ 315.445  Millions$ 12.914  Millions
Contineum Therapeutics Inc   24.33 $ 175.484  Millions$ 7.214  Millions
Anebulo Pharmaceuticals Inc   23.84 $ 11.628  Millions$ 0.488  Millions
Fulcrum Therapeutics Inc   23.83 $ 214.111  Millions$ 8.985  Millions
Trevi Therapeutics Inc   22.77 $ 203.885  Millions$ 8.955  Millions
Rapport Therapeutics Inc   21.92 $ 260.447  Millions$ 11.879  Millions
Keros Therapeutics Inc   21.88 $ 690.215  Millions$ 31.552  Millions
Newamsterdam Pharma Company N v   21.63 $ 739.162  Millions$ 34.175  Millions
Septerna Inc   21.59 $ 326.561  Millions$ 15.127  Millions
Tyra Biosciences Inc   21.52 $ 296.271  Millions$ 13.770  Millions
Prothena Corporation Public Limited Company  21.47 $ 371.435  Millions$ 17.298  Millions
Novabridge Biosciences  21.38 $ 23.300  Millions$ 1.090  Millions
Whitehawk Therapeutics Inc   20.24 $ 177.200  Millions$ 8.756  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.